EyePoint Pharmaceuticals (EYPT)
(Real Time Quote from BATS)
$18.18 USD
+0.58 (3.30%)
Updated May 1, 2024 02:30 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EYPT 18.18 +0.58(3.30%)
Will EYPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice
Other News for EYPT
Bullish Buy Rating Reaffirmed for EyePoint Pharmaceuticals with a $39 Price Target
Fly Insider: Zura Bio, Google among week's notable insider trades
EYPT Crosses Below Key Moving Average Level
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Commit To Purchase EyePoint Pharmaceuticals At $12.50, Earn 61% Annualized Using Options